Share Price and Basic Stock Data
Last Updated: December 18, 2025, 12:22 pm
| PEG Ratio | 1.49 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alpa Laboratories Ltd, currently trading at ₹79.2, operates within the pharmaceuticals industry and has a market capitalization of ₹167 Cr. The company’s revenue trajectory has shown fluctuations over recent quarters, with sales reported at ₹22 Cr in June 2022, peaking at ₹29 Cr in March 2023 before declining to ₹25 Cr in June 2023. However, the latest figures indicate a recovery, with sales rising to ₹32 Cr in September 2023. This volatility can be attributed to various factors within the pharmaceutical sector, including regulatory challenges and market competition. The trailing twelve months (TTM) revenue stands at ₹109 Cr, reflecting a modest increase from ₹93 Cr the previous year, suggesting an overall positive trend despite the recent quarterly dips. Investors should note that the company’s ability to stabilize and grow revenue will be crucial for its long-term sustainability.
Profitability and Efficiency Metrics
Profitability at Alpa Laboratories has been a mixed bag, with operating profit margins (OPM) reported at a low 2% overall. While the company achieved a peak OPM of 32% in March 2023, it has since struggled, dipping into negative margins in several quarters. The most recent OPM was recorded at 10% in September 2023, indicating some recovery. Despite these fluctuations, the return on equity (ROE) stands at a respectable 11.5%, showcasing the company’s ability to generate profits relative to shareholder equity. Notably, the interest coverage ratio (ICR) is an impressive 121.23x, suggesting that the company can comfortably meet its interest obligations, given its minimal borrowings of ₹2 Cr. However, the operating profit has seen a decline in recent quarters, leading to a cautious outlook on its efficiency metrics.
Balance Sheet Strength and Financial Ratios
Alpa Laboratories displays a strong balance sheet with total borrowings of just ₹2 Cr against reserves of ₹173 Cr, indicating a solid capital structure with low leverage. This is further highlighted by a debt-to-equity ratio that remains negligible, reflecting prudent financial management. The company’s current ratio of 4.10x suggests a comfortable liquidity position, enabling it to cover short-term liabilities. However, the cash conversion cycle (CCC) stands at 150 days, which may signal inefficiencies in inventory management or receivables collection. The price-to-book value (P/BV) ratio of 1.28x indicates that the stock is trading slightly above its book value, which could suggest a fair valuation, but investors should be mindful of the sector’s average P/BV range for a more comprehensive analysis.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Alpa Laboratories reveals a significant promoter stake of 57.29%, which indicates strong management control and alignment with shareholder interests. However, foreign institutional investors (FIIs) hold only 0.35%, and domestic institutional investors (DIIs) have virtually no stake, which raises questions about broader investor confidence. The public shareholding stands at 42.36%, with a total of 18,542 shareholders, suggesting a decent retail interest. Yet, the low institutional participation might reflect caution among larger investors regarding the company’s future growth prospects. The stability of promoter holdings can provide a cushion against volatility, but the absence of institutional backing could weigh on stock performance during market downturns.
Outlook, Risks, and Final Insight
Looking ahead, Alpa Laboratories faces a dual-edged sword of opportunities and risks. The recovery in sales and the impressive interest coverage ratio are positives, hinting at potential for improved profitability if operational efficiencies can be enhanced. However, the volatility in quarterly earnings and the low OPM raise concerns about the sustainability of its profit margins. Additionally, the cash conversion cycle suggests room for improvement in operational management. Investors should weigh these factors carefully; while the low debt levels provide a buffer, the company must address its efficiency metrics to unlock further growth. Overall, Alpa Laboratories presents a mixed investment case: its solid balance sheet and promoter backing are strengths, but the inconsistent profitability and low institutional confidence are risks that warrant close monitoring.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 117 | 235/84.3 | 32.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,205 Cr. | 386 | 479/192 | 87.1 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.7 Cr. | 45.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 47.8 Cr. | 32.6 | 33.0/17.0 | 114 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,981.65 Cr | 1,143.16 | 52.24 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 14 | 27 | 29 | 25 | 32 | 27 | 24 | 21 | 25 | 26 | 39 | 19 |
| Expenses | 21 | 19 | 25 | 20 | 27 | 29 | 25 | 20 | 21 | 22 | 25 | 39 | 19 |
| Operating Profit | 1 | -6 | 3 | 9 | -1 | 3 | 2 | 4 | 1 | 3 | 1 | -0 | 0 |
| OPM % | 6% | -42% | 10% | 32% | -5% | 10% | 9% | 15% | 3% | 13% | 3% | -1% | 2% |
| Other Income | 2 | 6 | 3 | -1 | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 3 | 12 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 0 | 5 | 8 | 3 | 6 | 5 | 7 | 5 | 10 | 9 | 2 | 12 |
| Tax % | -0% | -0% | -0% | 42% | -0% | -0% | 15% | 47% | -0% | 20% | -0% | 187% | -0% |
| Net Profit | 3 | 0 | 5 | 5 | 3 | 6 | 5 | 4 | 5 | 8 | 9 | -2 | 12 |
| EPS in Rs | 1.26 | 0.10 | 2.44 | 2.20 | 1.44 | 2.73 | 2.15 | 1.69 | 2.43 | 3.63 | 4.23 | -0.93 | 5.60 |
Last Updated: August 20, 2025, 1:55 pm
Below is a detailed analysis of the quarterly data for Alpa Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 20.00 Cr..
- For Expenses, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 39.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 20.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For OPM %, as of Jun 2025, the value is 2.00%. The value appears strong and on an upward trend. It has increased from -1.00% (Mar 2025) to 2.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 187.00% (Mar 2025) to 0.00%, marking a decrease of 187.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.60. The value appears strong and on an upward trend. It has increased from -0.93 (Mar 2025) to 5.60, marking an increase of 6.53.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 110 |
| Expenses | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | 105 | 112 |
| Operating Profit | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | -2 |
| OPM % | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 8% | 5% | -2% |
| Other Income | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 28 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit before tax | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 26 | 23 |
| Tax % | 4% | -48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | 19% | 24% | |
| Net Profit | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 20 | 19 |
| EPS in Rs | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 7.98 | 9.35 | 8.95 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 80.00% | 900.00% | -25.00% | -16.67% | -40.00% | 33.33% | 75.00% | 100.00% | -7.14% | 30.77% | 17.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 820.00% | -925.00% | 8.33% | -23.33% | 73.33% | 41.67% | 25.00% | -107.14% | 37.91% | -13.12% |
Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 55% |
| 5 Years: | 30% |
| 3 Years: | 36% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 27% |
| 3 Years: | 15% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 11:00 pm
Balance Sheet
Last Updated: December 10, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 161 | 173 |
| Borrowings | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 5 | 0 | 2 |
| Other Liabilities | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 25 | 51 | 52 |
| Total Liabilities | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
| Fixed Assets | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 21 | 21 |
| CWIP | -0 | 0 | -0 | -0 | -0 | 0 | 1 | 2 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 109 | 129 | 157 |
| Other Assets | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 72 | 83 | 70 |
| Total Assets | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
Below is a detailed analysis of the balance sheet data for Alpa Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2025) to 173.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 248.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 157.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 28.00 Cr..
- For Other Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 13.00 Cr..
- For Total Assets, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (173.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -26.00 | -17.00 | -4.00 | -2.00 | -1.00 | 6.00 | 8.00 | 5.00 | 5.00 | 4.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 186 | 138 | 155 |
| Inventory Days | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 | 73 | 92 |
| Days Payable | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 | 63 | 97 |
| Cash Conversion Cycle | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 170 | 149 | 150 |
| Working Capital Days | 65 | -4 | 224 | 197 | 204 | 189 | 121 | 137 | 124 | 150 | 132 | 108 |
| ROCE % | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 11% | 14% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Diluted EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Cash EPS (Rs.) | 10.32 | 8.90 | 6.61 | 7.48 | 4.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Revenue From Operations / Share (Rs.) | 53.45 | 51.68 | 44.18 | 53.36 | 46.36 |
| PBDIT / Share (Rs.) | 13.36 | 10.93 | 8.29 | 10.19 | 5.75 |
| PBIT / Share (Rs.) | 12.31 | 10.00 | 7.66 | 9.40 | 5.16 |
| PBT / Share (Rs.) | 12.20 | 9.83 | 7.55 | 9.30 | 5.13 |
| Net Profit / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| NP After MI And SOA / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| PBDIT Margin (%) | 24.98 | 21.14 | 18.76 | 19.09 | 12.39 |
| PBIT Margin (%) | 23.03 | 19.35 | 17.33 | 17.61 | 11.13 |
| PBT Margin (%) | 22.82 | 19.01 | 17.09 | 17.42 | 11.05 |
| Net Profit Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| NP After MI And SOA Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| Return on Networth / Equity (%) | 11.37 | 11.04 | 9.34 | 11.57 | 6.73 |
| Return on Capital Employeed (%) | 14.72 | 13.63 | 11.90 | 15.97 | 10.07 |
| Return On Assets (%) | 8.76 | 9.19 | 7.52 | 9.07 | 5.16 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.03 | 0.01 | 0.04 | 0.00 |
| Asset Turnover Ratio (%) | 0.55 | 0.62 | 0.57 | 0.73 | 0.71 |
| Current Ratio (X) | 4.10 | 5.74 | 4.67 | 4.43 | 3.73 |
| Quick Ratio (X) | 3.72 | 5.25 | 4.28 | 3.93 | 3.22 |
| Inventory Turnover Ratio (X) | 4.52 | 4.78 | 3.73 | 3.96 | 3.73 |
| Interest Coverage Ratio (X) | 121.23 | 64.02 | 78.01 | 97.84 | 155.24 |
| Interest Coverage Ratio (Post Tax) (X) | 85.14 | 47.71 | 57.27 | 65.32 | 94.03 |
| Enterprise Value (Cr.) | 216.89 | 179.04 | 106.65 | 149.57 | 65.56 |
| EV / Net Operating Revenue (X) | 1.93 | 1.65 | 1.15 | 1.33 | 0.67 |
| EV / EBITDA (X) | 7.72 | 7.79 | 6.11 | 6.98 | 5.42 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| Price / BV (X) | 1.28 | 1.16 | 0.84 | 1.20 | 0.70 |
| Price / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| EarningsYield | 0.08 | 0.09 | 0.11 | 0.09 | 0.09 |
After reviewing the key financial ratios for Alpa Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has increased from 8.90 (Mar 24) to 10.32, marking an increase of 1.42.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 53.45. It has increased from 51.68 (Mar 24) to 53.45, marking an increase of 1.77.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 13.36, marking an increase of 2.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.31. This value is within the healthy range. It has increased from 10.00 (Mar 24) to 12.31, marking an increase of 2.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.20. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 12.20, marking an increase of 2.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 24.98. This value is within the healthy range. It has increased from 21.14 (Mar 24) to 24.98, marking an increase of 3.84.
- For PBIT Margin (%), as of Mar 25, the value is 23.03. This value exceeds the healthy maximum of 20. It has increased from 19.35 (Mar 24) to 23.03, marking an increase of 3.68.
- For PBT Margin (%), as of Mar 25, the value is 22.82. This value is within the healthy range. It has increased from 19.01 (Mar 24) to 22.82, marking an increase of 3.81.
- For Net Profit Margin (%), as of Mar 25, the value is 17.34. This value exceeds the healthy maximum of 10. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.34. This value is within the healthy range. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.37. This value is below the healthy minimum of 15. It has increased from 11.04 (Mar 24) to 11.37, marking an increase of 0.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.72. This value is within the healthy range. It has increased from 13.63 (Mar 24) to 14.72, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 8.76, marking a decrease of 0.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.55. It has decreased from 0.62 (Mar 24) to 0.55, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.10. This value exceeds the healthy maximum of 3. It has decreased from 5.74 (Mar 24) to 4.10, marking a decrease of 1.64.
- For Quick Ratio (X), as of Mar 25, the value is 3.72. This value exceeds the healthy maximum of 2. It has decreased from 5.25 (Mar 24) to 3.72, marking a decrease of 1.53.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.52. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.52, marking a decrease of 0.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 121.23. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 121.23, marking an increase of 57.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 85.14. This value is within the healthy range. It has increased from 47.71 (Mar 24) to 85.14, marking an increase of 37.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 216.89. It has increased from 179.04 (Mar 24) to 216.89, marking an increase of 37.85.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 1.93, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 7.79 (Mar 24) to 7.72, marking a decrease of 0.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For Price / BV (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.28, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 24) to 0.08, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alpa Laboratories Ltd:
- Net Profit Margin: 17.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.72% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.37% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 85.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 8.77 (Industry average Stock P/E: 42.98)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 33/2, Pigdamber, A.B.Road, Rau, Indore Madhya Pradesh 453446 | is@alpalabs.in http://www.alpalabs.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra Singh Chawla | Chairman |
| Mr. Paresh Chawla | Managing Director |
| Mr. Pravin Shah | Director |
| Mr. Vitthal Kothana | Director |
| Mr. Shitul Shah | Director |
| Mrs. Jyoti Jain | Independent Director |
| Mr. Sanket Baheti | Independent Director |
| Mr. Pratik Shah | Independent Director |
| Mrs. Pratibha Lunawat | Independent Director |
| Mr. Sunil Kumar Valecha | Independent Director |
FAQ
What is the intrinsic value of Alpa Laboratories Ltd?
Alpa Laboratories Ltd's intrinsic value (as of 18 December 2025) is 75.71 which is 3.43% lower the current market price of 78.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 165 Cr. market cap, FY2025-2026 high/low of 137/75.0, reserves of ₹173 Cr, and liabilities of 248 Cr.
What is the Market Cap of Alpa Laboratories Ltd?
The Market Cap of Alpa Laboratories Ltd is 165 Cr..
What is the current Stock Price of Alpa Laboratories Ltd as on 18 December 2025?
The current stock price of Alpa Laboratories Ltd as on 18 December 2025 is 78.4.
What is the High / Low of Alpa Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alpa Laboratories Ltd stocks is 137/75.0.
What is the Stock P/E of Alpa Laboratories Ltd?
The Stock P/E of Alpa Laboratories Ltd is 8.77.
What is the Book Value of Alpa Laboratories Ltd?
The Book Value of Alpa Laboratories Ltd is 92.0.
What is the Dividend Yield of Alpa Laboratories Ltd?
The Dividend Yield of Alpa Laboratories Ltd is 0.00 %.
What is the ROCE of Alpa Laboratories Ltd?
The ROCE of Alpa Laboratories Ltd is 15.0 %.
What is the ROE of Alpa Laboratories Ltd?
The ROE of Alpa Laboratories Ltd is 11.5 %.
What is the Face Value of Alpa Laboratories Ltd?
The Face Value of Alpa Laboratories Ltd is 10.0.